A Comparative Study Between Homoeopathic Medicines Praeira Brava and Chimaphila Umbellata in Case Of Benign Prostatic Hyperplasia

A Randomised Comparative Study To Assess The Effectiveness Of Homoeopathic Medicine Pareira Brava and Chimaphila Umbellata in Case Of Benign Prostatic Hyperplasia - NIL

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2025/03/082381

Enrollment

Registered

2025-03-17

Start date

Unknown

Completion date

Unknown

Last updated

2025-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: N401- Benign prostatic hyperplasia withlower urinary tract symptoms Health Condition 2: N400- Benign prostatic hyperplasia without lower urinary tract symptoms Health Condition 3: N403- Nodular prostate with lower urinary tract symptoms Health Condition 4: N402- Nodular prostate without lower urinary tract symptoms

Interventions

Intervention1: PAREIRA BRAVA: All the eligible patient having symptoms of Benign prostatic hyperplasia will be prescribed Pareira Brava. The prescription will be based upon characteristic symptom of t

Eligibility

Inclusion criteria

Inclusion criteria: 1) Patients giving consent for the study. 2) Cases are taken irrespective of socio-economic and religion status. 3)Cases of BPH based on following symptoms : a. Frequency b. Incomplete emptying c. Nocturia d. Intermittency e. Urgency f. Pain (Dysuria) g. Haematuria h. Straining i. Retention of urine (not more than 24 hr) 4) Pre diagnosed case of BPH are under modern medicine treatment but have no relief seeking for homoeopathic treatment.

Exclusion criteria

Exclusion criteria: 1) Cases undergone prior surgeries for BPH. 2) Cases undergone bladder surgeries. 3) Cases which are complicated with stricture. 4) Complete urine retention for more than 24 hours i.e anuria 5) Cases with any other severe systemic disorder already diagnosed or diagnosed during screening if clinical features are suggestive of some systemic illness .To confirm, investigations regarding the same . 6) Patient pursuing other treatment and are not willing to leave it.

Design outcomes

Primary

Measure	Time frame
According to the scores obtained (pre and Post) from International Prostate Symptom score (IPSS)Timepoint: Pre Scores would be taken at the baseline of treatment and post scores would be taken at the end of 12 weeks by International Prostate Symptom Score (IPSS)	—

Secondary

Measure	Time frame
To assess the efficacy of PAREIRA BRAVA & CHIMAPHILA UMBELLATA in cases of Benign Prostatic HyperplasiaTimepoint: 12 months	—

Countries

India

Contacts

Public ContactDr Hemlata Kumawat

Dr Madan Pratap Khuteta Homoeopathic Medical College Hospital and Research Centre

PMpg2724dept@gmail.com9829053664

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026